Patent: 6,531,477
✉ Email this page to a colleague
Summary for Patent: 6,531,477
Title: | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
Abstract: | The present invention relates to the synthesis of a novel class of pyrazolo[3,4-d]pyrimidin-4-ones of formula (I), alternatively represented by the tautomer (II): ##STR1## that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cyclin dependent kinase 1-8 and their regulatory subunits know as cyclins A-H, K, N, and T. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents. |
Inventor(s): | Markwalder; Jay A. (London University, PA), Seitz; Steven P. (Swarthmore, PA), Sherk; Susan R. (Wilmington, DE) |
Assignee: | DuPont Pharmaceuticals Company (Wilmington, DE) |
Application Number: | 09/416,584 |
Patent Claims: | see list of patent claims |
Details for Patent 6,531,477
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2018-10-13 |
Servier Pharmaceuticals Llc | ONCASPAR | pegaspargase | Injection | 103411 | 02/01/1994 | ⤷ Try a Trial | 2018-10-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |